Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Leases (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Current Leases for 9 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 226.74% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Dec 2025, up 226.74%, and an annual FY2025 reading of $3.1 million, up 106.43% over the prior year.
  • Current Leases was $3.3 million for Q4 2025 at Enanta Pharmaceuticals, up from $3.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $5.4 million in Q2 2023 and bottomed at $1.0 million in Q4 2024.
  • Average Current Leases over 5 years is $3.5 million, with a median of $3.4 million recorded in 2021.
  • The sharpest move saw Current Leases tumbled 79.74% in 2024, then surged 226.74% in 2025.
  • Year by year, Current Leases stood at $3.5 million in 2021, then increased by 0.49% to $3.5 million in 2022, then skyrocketed by 42.46% to $5.0 million in 2023, then crashed by 79.74% to $1.0 million in 2024, then soared by 226.74% to $3.3 million in 2025.
  • Business Quant data shows Current Leases for ENTA at $3.3 million in Q4 2025, $3.1 million in Q3 2025, and $2.4 million in Q2 2025.